---
schema_version: "secwatch.filing_event.v1"
accession: "0001711279-24-000009"
form_type: "8-K"
ticker: "KRYS"
cik: "0001711279"
company_name: "Krystal Biotech, Inc."
filed_at: "2024-02-26T23:59:59+00:00"
generated_at: "2026-06-05T15:22:30.174095+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Krystal Biotech reports Q4 net product revenue of $42.1M from VYJUVEK; net income of $8.7M

## Summary
- Net product revenue $42.1M in Q4 2023; $50.7M full year 2023; gross margin 93% in Q4.
- FDA aligned on single-arm study to approve B-VEC eyedrops for ocular DEB in ~10 patients; study starts 2H 2024.
- Cash & investments $594.1M at year-end; net income $8.7M in Q4 vs net loss of $32.1M in prior-year quarter.
- First patient dosed in Phase 1 KB408 for AATD; FDA granted ODD. Interim data expected 2H 2024.
- FY2024 non-GAAP R&D+SG&A guidance $150M-$175M.

## SEC filing metadata
- accession: 0001711279-24-000009
- form_type: 8-K
- ticker: KRYS
- cik: 0001711279
- company_name: Krystal Biotech, Inc.
- filed_at: 2024-02-26T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000009/0001711279-24-000009-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000009/krys-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001711279-24-000009
- JSON: https://secwatch.observer/filing/0001711279-24-000009.json
- Plain text: https://secwatch.observer/filing/0001711279-24-000009.txt

## Key facts
- Earnings Releases
  Krystal Biotech, Inc. reported the quarter and year ended December 31, 2023 results: revenue $42.1M in 4Q and $50.7M for the year.
  - Period: the quarter and year ended December 31, 2023
  - Revenue: $42.1M in 4Q and $50.7M for the year
  - Result: reported results
  source text: in such filing. --- EX-99.1 (EX-99.1) --- Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates • Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of the use of B-VEC eyedrop formulation • Reached alignment with FDA to enable approval of B-VEC
  evidence_url: https://www.sec.gov/Archives/edgar/data/1711279/000171127924000009/0001711279-24-000009-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.